Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

#22-383 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

#22-382 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

Valmet strengthens its automation offering by acquiring NovaTech Automation’s Process Solutions business

Valmet Oyj’s press release on November 9, 2022 at 4:30 p.m. EETValmet entered into an agreement on November 9[th] to acquire the U.S. based NovaTech Automation’s Process Solutions business. The value of the acquisition will not be disclosed. The acquisition is estimated to be completed on January 1st, 2023 at the earliest. NovaTech Automation’s Process Solutions business specializes in process control and optimization solutions for batch, continuous and hybrid processes. The Process Solutions business has a turnover of approximately USD 18 million and employs more than 90 people in the

Implantica presents the third quarter 2022 on November 15 at 15:00 CET

Implantica AG (publ) invites investors to a presentation of the third quarter 2022 at 15:00 CET on November 15. The interim report for the third quarter will be published at 8:00 a.m. CET on the same day.The presentation will be in English via an audiocast with teleconference:   Conference call dial-in: · Sweden: +46 8 505 583 57 · United Kingdom: +44 3333 009273 · United States: +1-646-722-4903   Webcast: · https://ir.financialhearings.com/implantica-q3-2022   Speakers: · CEO Peter Forsell · CFO Andreas Öhrnberg · VP Operations & IR Nicole

International electrolyzer manufacturer will evaluate Smoltek’s carbon nanofibers

This press release is an English version of the previously published Swedish version, which has interpretive precedence. Smoltek Nanotech Holding AB ("Smoltek") announces that the group company Smoltek Hydrogen has initiated a collaboration with a company whose extensive build-up of production capacity will make them one of Europe’s largest manufacturers of electrolyzers. The manufacturer has ordered material samples of Smoltek’s cell material for electrolyzers, which they will integrate with their own technology into complete electrolyzer cells. When the manufacturer has carried out

Conversion of all series A shares to series B shares

Serneke Group AB has received a request from the series A shareholders to convert all shares of series A in Serneke to series B shares, in accordance with the conversion clause in Serneke’s articles of association.The board has decided to start the process of conversion, that will take place as soon as possible. After the conversion there will be no series A shares in the company. The total number of shares (28,753,232) is not affected, but all shares will be series B shares. A share of series A carries one (1) vote and a share of series B carries one tenth (0.1) vote. After the

The Finnish Financial Supervisory Authority has approved a supplement to the merger prospectus

Endomines AB, Stock Exchange Release 9 November 2022 15:00 CEST   The Finnish Financial Supervisory Authority has today, 9 November 2022, approved a supplement to the merger prospectus concerning the merger between Endomines AB (publ) (“Endomines”) and Endomines Finland Plc. As communicated through a press release on 18 August 2022, Endomines’ Board of Directors has decided on a re-domiciliation of the parent company from Sweden to Finland through a cross-border down-stream merger. The Finnish Financial Supervisory Authority has today approved and registered the supplement to the

OXE MARINE IMPLEMENTS BIODIESEL IN ALL TESTING, REDUCING NET CO2 EMISSIONS BY UP TO 94% COMPARED TO GASOLINE ALTERNATIVES

Following OXE Marine AB (publ)’s recently published sea trials where the company’s 300 hp diesel outboard OXE300 was tested against a gasoline outboard of equivalent power, where OXE Marine showed not only a 50% higher consumption in the gasoline outboard but a reduction of 92% net CO\2 \emissions compared to the gasoline alternative, the outboard manufacturers have decided to implement HVO100 in all development and testing. As a step in the engineering process, OXE Marine performs extensive testing of their diesel outboards OXE200 and OXE300. Due to the efficient diesel powerhead, OXE

Board members, management and other employees acquire warrants

On 19 May 2022, the Annual General Meeting of Safeture AB (publ) (“Safeture” or the “Company”) resolved, following proposals from the Board of Directors and the Nomination Committee respectively, to adopt two long-term incentive programs consisting of warrants. One incentive program for the Board members of the Company, and one incentive program for the management and other employees in the Company. The warrants have now been offered to, and subscribed for, by participants in both incentive programs.Three (3) Board members have subscribed for, in total, 250,000 warrants of series 2022/2025

Second instalment of dividend

At the Annual General Meeting on 13 May 2022 it was decided that the dividend of GBP 0.337 per share/SDR would be paid out in two equal instalments. The first payment was distributed on 20 May 2022. The following dates apply to the second instalment: · Ex-dividend date is 14 November 2022 · Record date is 15 November 2022 · Distribution by Euroclear Sweden AB on 18 November 2022 For accounting purposes, the rate of exchange to be used shall be the SEK-GBP rate prevalent on 14 November 2022.

BAMLET in the drinking water; protection against intestinal cancer and potent beneficial health effects

Colorectal cancer is a leading cause of death world-wide and more than 180,000 cases are diagnosed annually in the US alone. We now show that daily, long-term treatment with BAMLET in the drinking water inhibits intestinal tumor development in mice genetically susceptible to intestinal tumors, compared to mice not receiving BAMLET. The frequency of tumors and the tumor size was reduced already after short-term BAMLET treatment but with continued treatment, the mice remained symptom-free and survived significantly longer than control mice.Targeting early, locally growing tumors is essential

TOOsonix announces granted patents for its non-invasive treatments of dermatological conditions

TOOsonix A/S secures intellectual property rights in USA, Europe and China. The patents define methods for non-invasive and real-time image-guided treatment of skin using therapeutic ultrasound.Hoersholm, Denmark, November 9[th], 2022 - TOOsonix A/S, a pioneer in high intensity focused ultrasound (HIFU) technology for dermatology, today announced that the United States Patent and Trademark Office (USPTO) has granted a U.S. patent no. 11/491,351 regarding its key technologies. The U.S. patent and already granted patents in Europe and China therefore complete the first phase of securing

Mentice Receives Grant from Sweden’s Innovation Agency to Improve Synthetic Image Generation

Mentice has received a 3 million SEK grant from the Swedish government agency for innovation, Vinnova, to improve realism in Mentice virtual reality software environment with a focus on synthetic image generation. Mentice will be a part of a joint European research project called the TASTI project, financed by Vinnova within the Eureka Xecs cluster.   “The work to be done in the scope of the TASTI project will further increase the realism of our solutions in several ways. It will not only improve our current products but will open doors to new applications, where our synthetic images are

Nightingale Health Plc – Managers’ transactions – Jeffrey Barrett

Nightingale Health Plc – Managers' Transactions – 9 November 2022 3:00 p.m. (EET) ____________________________________________ Person subject to the notification requirement Name: Barrett, Jeffrey Position: Other senior manager   Issuer: Nightingale Health Oyj LEI: 743700WUIPC24LVMLO66 Notification type: INITIAL NOTIFICATION Reference number: 21059/7/8 ____________________________________________   Transaction date: 2022-11-07 Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME) Instrument type: SHARE ISIN: FI4000490875 Nature of the transaction:

VibroSense Dynamics takes the first order from Finland

The Clinic for Neurophysiology at Oulu University Hospital in Finland purchases the VibroSense Meter ® II instrument. The order includes a full license with access to all hand and foot examinations and has a total value of approximately SEK 420,000 including annual license revenue.The total order value is divided into two parts: SEK 184,000 for the purchase and start-up of the instrument, and approximately SEK 240,000 for the license and service agreement calculated over 10 years. Oulu University Hospital (OYS) is the northernmost of five university central hospitals in Finland. The area

EQL Pharma out-license Mellozzan to a leading European pharmaceutical Company for two major Southern European geographies

EQL Pharma has today entered into an exclusive out-licensing agreement with a leading European pharmaceutical company for EQL's proprietary product Mellozzan (melatonin) for two major geographies in Southern Europe. The agreement is in practice without a set time limit and applies to tablets in six different strengths as well as an oral solution. Both formulations are ready to send in for registration in the two countries.Mellozzan is a medicine given to children with sleep disorders who have ADHD and where sleep hygiene measures are not enough. In the ADHD patient group insomnia is very

CORRECTION: Information regarding the exercise period of warrants of series TO 1 in Genetic Analysis

The press release published on November 2, 2022, at 08:00 CET, incorrectly stated November 16, 2022, as the last day of trading in warrants of series TO 1. The last day of trading in warrants of series TO 1 is November 14, 2022. The full press release, updated to reflect the correct date, follows below.Oslo, Norway, November 2, 2022 - On November 2, 2022, the exercise period for the warrants of series TO 1 issued in connection with Genetic Analysis AS's ("GA" or the "Company") IPO in September/October 2021 will commence. The exercise period runs until 16 November 2022. Holders of series

Nexam to Cleveland - giving talks for the growing US market

"Customize the properties of your recycled plastics with the help of Reactive Recycling" is the title of Henrik Bernqvist, Business manager at Nexam's talk in Cleveland, Ohio. Nasdaq First North-listed Nexam Chemical is once again invited by the organization AMI to share its expertise in recycling at the Plastic Recycling World Expo. Nexam also participates with its own stand.North America is an important region for Nexam Chemical, where the company helps plastic manufacturers improve their products - both in terms of durability and function. The presentation will describe what companies in

Medivir presents new data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC Immunotherapy Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the poster, titled “Fostrox (MIV-818) in combination with anti-PD-1 shows increased efficacy in nonclinical tumour models in vivo” will be presented at the SITC 2022 conference, on November 10 by Fredrik Öberg, CSO at Medivir. Fostroxacitabine bralpamide (fostrox) is an orally administered liver-targeted troxacitabine-based nucleotide prodrug currently undergoing phase 1/2a clinical trial in

Reporting of transactions in LED iBond International A/S shares by persons with managerial responsibilities

In connection with LED iBond International A/S’ rights issue, the following transactions have been completed:Name Michael BragReason for Chairman of the board ofnotification directors in LED iBond International A/SIssuer LED iBond International A/SIdentification DK0061274529 (temporary ISIN)codeInstrument Shares and subscription rightsNature of the PurchasetransactionDate of the 4 November 2022transactionPlace of the First North Growth Markettransaction DenmarkAggregated 1,434,060 sharesvolume

Saga Pure: Contemplating establishment and subsequent listing of new investment company

(Oslo, 9 November 2022) Saga Pure ASA (Saga Pure, OSE: SAGA) today announces the intention to establish a new industrial investment company focused on distressed assets, with the ambition of a separate listing on Euronext Growth in the first quarter of 2023. The new company will have NOK 500 million in equity in form of cash.Highlights · Saga Pure ASA has since its inception in the fourth quarter of 2020 realized net gains of NOK 490 million, contributing to a cash position of NOK 780 million as per primo November 2022. · The Board of Directors considers the company to be

One RescueRunner system sold to Norwegian rescue organization

Safe at Sea AB (publ) has through their Norwegian distributor received an order for one (1) RescueRunner system for Red Cross Hordaland.The demand for RescueRunner is constantly increasing in Norway and the Red Cross Hordaland is one of the organizations that decided to invest in a RescueRunner system. We are very proud that the Red Cross Hordaland in Norway now chooses to buy a RescueRunner as a search and rescue boat. Hordaland is located west of Oslo where the tough operational environment requires a robust and flexible boat like the RescueRunner. "We are very pleased that the Red

Safello reaches new milestone with 300 000 customers in Sweden

Stockholm, 9 November 2022 | Sweden’s leading crypto broker Safello  reached a significant milestone today when the number of customers reached 300,000. Nearly 3% of the Swedish population has now been onboarded to Safello's platform. The interest in cryptocurrencies continues to rise in Sweden and on average Safello onboarded around 5,000 users per month so far during 2022. Since the launch of a user-friendly onboarding experience in 2018, using Swish and BankID, Safello has added more than 240,000 customers, representing more than 400% growth in the number of

SpareBank 1 SR-Bank (SRBNK) - Distribution of shares as part of the savings scheme for employees

The shares purchased by SpareBank 1 SR-Bank ASA 1 November, 2 November and 3 November 2022 for use in the group's savings scheme for employees, have been distributed to the employees at a price of NOK 106,2741. After allocation the banks total holding of own shares is 28 720 shares. As participants in the savings scheme the primary insiders have acquired shares in accordance with the enclosed list.

There are no items matching the current filter
There are no more items matching the current filter
Back to top